CNC Centene Corporation
A Medicaid giant at trough margins; if repricing restores about 2.8%, the stock looks modestly undervalued.
The story
Centene is the largest US Medicaid managed-care and ACA Marketplace insurer, a scale, low-margin business whose edge is state contracting relationships and cost-of-care management rather than pricing power. After a 2025 reset driven by Marketplace risk-adjustment shortfalls, elevated Medicaid acuity following redeterminations, and Part D redesign, it is a mature company working through a cyclical margin trough. The repricing of rates and benefits should restore margins toward historical levels, while Marketplace membership shrinks as enhanced subsidies expire.
I set year-one growth flat because Marketplace attrition offsets Medicaid rate increases. Growth then settles at about 3.5% in a mature, government-funded market. The target margin of 2.8% matches Centene's pre-shock 2022-2024 range rather than any peak, and it takes about four years to get there as repricing catches up with acuity. Because the business is asset-light, sales-to-capital stays near 5. A 5% failure probability allows for regulatory and Medicaid-funding tail risk.
Value drivers
| Revenue growth (Y1) | 0.0% |
| Terminal growth | 3.5% |
| Forecast horizon | 6y |
| Target operating margin | 2.8% |
| Years to target margin | 4 |
| Sales-to-capital | 5.00 |
| Beta | 0.90 |
| Failure probability | 5.0% |
| Cost of capital (WACC) | 7.9% |
| Terminal WACC | 8.2% |
Valuation bridge
| PV of explicit FCFF | 8.31B |
| PV of terminal value | 39.65B |
| Equity value | 45.85B |
| ÷ shares → per share | $92.81 |
Projected free cash flow to the firm
| Yr | Revenue | Growth | Margin | NOPAT | Reinvest | FCFF | PV |
|---|---|---|---|---|---|---|---|
| 1 | 202.94B | 0.0% | -0.8% | -1.23B | 0 | -1.23B | -1.14B |
| 2 | 204.36B | 0.7% | 0.4% | 678.29M | 284.11M | 394.18M | 338.41M |
| 3 | 207.22B | 1.4% | 1.6% | 2.64B | 572.20M | 2.06B | 1.64B |
| 4 | 211.57B | 2.1% | 2.8% | 4.68B | 870.32M | 3.81B | 2.81B |
| 5 | 217.50B | 2.8% | 2.8% | 4.81B | 1.18B | 3.63B | 2.48B |
| 6 | 225.11B | 3.5% | 2.8% | 4.98B | 1.52B | 3.46B | 2.19B |
Key risks
- Federal Medicaid funding cuts and work requirements reduce enrollment and squeeze state rates
- Medicaid acuity and utilization keep outrunning rate increases, so margins stall below 2%
- Marketplace morbidity worsens as healthier members leave after subsidies expire, causing further risk-adjustment shortfalls
Catalysts
- 2026-2027 Medicaid rate cycles that reflect actual acuity
- Marketplace repricing and membership shedding that restore a positive segment margin